Applied dna to showcase linea ivt as a high-yield, dsrna-mitigated platform for the gmp manufacture of rna at the 3rd annual mrna process development & manufacturing summit

- co-hosts seminar with mrna cdmo kudo bio to demonstrate linea ivt capability for rapid mrna manufacturing - stony brook, ny / accesswire / september 17, 2024 / applied dna sciences, inc. (nasdaq:apdn) (applied dna), a leader in pcr-based dna technologies, today announced its participation at upcoming mrna events in boston this week: 3rd annual mrna process development & manufacturing summit - members of applied dna's biotherapeutics sales and business development teams (collectively 'linearx,' a majority-owned applied dna company) will attend the 3rd annual mrna process development & manufacturing summit taking place september 17-19, 2024. linearx will present its linea™ ivt platform - a combination of an enzymatically produced dna template (linea™ dna ivt template) coupled with a next-generation rna polymerase (linea™ rnap) - as a solution to enable mrna producers to manufacture better mrna faster via simplified workflows and reduced double-stranded rna (dsrna) contamination.
APDN Ratings Summary
APDN Quant Ranking